The rate of gastric emptying is an important determinant of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion and may influence the magnitude of glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors.
type 2 diabetes (4). Moreover, GLP-1 has the capacity to slow gastric emptying (8, 9) , suppress glucagon (10) , and appetite (11) and may even diminish hepatic glucose production independently of changes in insulin and glucagon (12) .
Notably, both GIP and GLP-1 undergo rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) (13, 14) . Accordingly, preservation of intact GIP, and particularly GLP-1, by DPP-4 inhibitors improves glycemic control in type 2 diabetes (15) . GLP-1 appears to mediate about 50% of the insulinotropic and glucose-lowering effects associated with DPP-4 inhibition (16, 17) . Furthermore, stimulation of GLP-1 secretion (eg, by small macronutrient preloads ingested before the main meal) potentiates the lowering of blood glucose by DPP-4 inhibitors (18, 19) .
The rate of emptying of orally ingested glucose from the stomach varies from 1 to 4 kcal/min between individuals in health and even more widely in patients with type 2 diabetes, in whom gastric emptying is frequently delayed and sometimes accelerated (20) . Gastric emptying is a key determinant of the postprandial glycemic response to oral glucose (21) . In humans, the amplitude of incretin secretion is largely dependent on direct nutrient stimulation of GIP-releasing K-cells in the proximal gut, and GLP-1-secreting L-cells more distally, and is, therefore, influenced by the rate of entry of nutrients into the small intestine (1) . GIP secretion increases approximately in proportion to the rate of intraduodenal (ID) glucose entry, whereas the GLP-1 response is minimal when ID glucose is administered at 1-2 kcal/min but considerably greater at 3-4 kcal/ min (22) (23) (24) . Not surprisingly, the incretin effect is substantially greater during ID glucose infusion at 4 than 2 kcal/min (3) . Therefore, it might be assumed that the glucose-lowering efficacy of DPP-4 inhibitors will be greater in type 2 diabetic patients with relatively more rapid gastric emptying, notwithstanding that more rapid emptying increases glycemia (25) . We have recently shown that when ID glucose is administered at 2 kcal/min, the lowering of blood glucose by the DPP-4 inhibitor, sitagliptin, was marked in healthy lean and nondiabetic obese subjects but marginal in patients with type 2 diabetes, probably because stimulation of GLP-1 is modest at this rate of ID glucose infusion (26) .
In the present study, we hypothesized that the glucose-lowering efficacy of a DPP-4 inhibitor would be augmented by increasing the rate of glucose entry into the small intestine, associated with increased GLP-1 secretion. We compared the effects of a single dose of the DPP-4 inhibitor, vildagliptin (VILD), on plasma glucose, insulin, and incretin hormone concentrations, during ID glucose infusion at 2 different rates (2 and 4 kcal/min) approximating the lower-mid and upper ends of the physiological range of gastric emptying, in patients with type 2 diabetes.
Materials and Methods

Participants
A total of 17 diet-controlled type 2 diabetic patients were recruited into this double-blind, randomized, crossover trial after providing written, informed consent. Sixteen patients (11 males and 5 females, 65.5 Ϯ 2.4 y, BMI 30.4 Ϯ 1.5 kg/m 2 , HbA1 6.3 Ϯ 0.1% [45.6 Ϯ 1.6 mmol/mol], and duration of known diabetes 5.1 Ϯ 1.4 y) completed the study, and 1 was excluded due to occurrence of an acute coronary syndrome 5 days after the second study visit. None had impaired liver or renal function, diabetic complications, was a smoker, or was taking any medication known to affect gastrointestinal function. The protocol ( Figure 1 ) was approved by the Human Research Ethics Committee of the Royal Adelaide Hospital.
Protocol
Subject were studied on 4 occasions, each separated by at least 7 days. On the evening before each study day (ϳ7 PM), each subject consumed a standardized meal (MaCain Foods). Subjects then fasted until the next morning, when they attended the laboratory at approximately 8 AM. A multilumen silicone rubber catheter (Dentsleeve International) was inserted transnasally and allowed to pass into the duodenum by peristalsis, with its position monitored continuously by measurement of antral and duodenal transmucosal potential differences, as described (27) . An infusion port was positioned 12 cm distal to the pylorus.
An iv cannula was inserted for blood sampling. After withdrawing a baseline sample, VILD 50 mg or a matching placebo (PLBO) tablet was administered orally with 30-mL water (at t ϭ Ϫ60 min). At t ϭ 0 minutes, an ID glucose infusion (either 60-or 120-g glucose dissolved in water to the same volume of 480 Figure 1 . Outline of study protocol. On each study day, a nasoduodenal catheter was positioned with an infusion port located 12 cm beyond the pylorus. At t ϭ Ϫ60 minutes, either 50-mg VILD or a matching PLBO tablet was given, followed by an ID glucose infusion at a rate of either 2 or 4 kcal/min (ID2 or ID4) between t ϭ 0 and 120 minutes. Venous blood was obtained at frequent intervals for measurements of plasma glucose, insulin, C-peptide, glucagon, GIP, and GLP-1. mL, with osmolality matched at ϳ1390 mOsmol/L using sodium chloride) was commenced and maintained for 120 minutes (t ϭ 0 -120 min; ie, 2 kcal/min [ID2] or 4 kcal/min [ID4]). The volume of ID2 and ID4 infusions was matched, because it influences small intestinal distension and transit (28) . Additional venous blood was sampled at t ϭ 0, 15, 30, 45, 60, 75, 90, and 120 minutes. Blood samples were collected into ice-chilled EDTA tubes for plasma glucose and hormone measurements, with 10-L/mL DPP-4 inhibitor (DPP-4 -010; Linco Research) added to tubes for measurement of intact GLP-1 (intact GIP measurement was not performed due to logistical issues). Plasma was separated within 15 minutes of collection and stored at Ϫ80°C for subsequent analysis. The clinical trial registration number is ACTRN12613001158752 (www.anzctr.org.au).
Measurements
Plasma glucose concentrations were measured by the glucose oxidase technique (2300 STAT Plus). Plasma insulin was measured by ELISA immunoassay (10 -1113; Mercodia), with sensitivity 1.0 mU/L, and intra-and interassay CVs of 1.3% and 7.6%, respectively. Plasma C-peptide was measured by ELISA immunoassay (10 -1136-01; Mercodia), with sensitivity 15 pmol/L, and intra-and interassay coefficients of variation (CVs) of 4.6% and 8.1%, respectively. Plasma glucagon was measured by RIA (GL-32K; Millipore), with sensitivity 20 pg/mL, and intra-and interassay CVs of 3.9% and 8.4%, respectively. Plasma total GIP was measured by RIA using a modification of a previously published method (29) , with sensitivity 2 pmol/L, and intra-and interassay CVs of 4.8% and 9.9%, respectively. Plasma total GLP-1 was measured by RIA (GLP1T-36HK; Millipore), with sensitivity 3 pmol/L, and intra-and interassay CVs of 5.4% and 7.4%, respectively. Plasma intact GLP-1 was measured by RIA (GLP1A-35HK; Millipore), with sensitivity 3 pmol/L, and intra-and interassay CVs of 2.0% and 4.3%, respectively.
Statistical analysis
Incremental areas under the curve (iAUCs) for plasma glucose and hormones, which reflect the changes from baseline, were calculated using the trapezoidal rule. Insulin secretion rates (ISRs) were calculated from C-peptide concentrations using ISEC 3.4a software, supplied by Dr Roman Hovorka, London, United Kingdom (30) . Population-derived coefficients of transition between compartments were used as described (31, 32) . The ISR to glucose ratio was also calculated to compare insulin secretion while correcting for differences in plasma glucose concentrations between the 4 study days. Fasting plasma glucose and hormone levels were compared using one-factor repeated-measures ANOVA. The iAUCs for plasma glucose and hormones, as well as the peak plasma glucose concentrations, were compared using two-factor repeated-measures ANOVA, with the ID glucose infusion rate and treatment with VILD or PLBO as factors. Repeated-measures ANOVA with treatment and time as factors was also used to compare differences in these parameters between the 4 study days. Post hoc paired comparisons, adjusted for multiple comparisons by Bonferroni-Holm's correction, were performed if ANOVAs revealed significant effects. Relationships between variables were assessed using univariate linear regression analysis. Based on our previous work (26) , a sample size of 16 subjects was calculated to have at least 80% power (at ␣ ϭ 0.05) to detect a 50% increase in the proportional reduction in the iAUC for plasma glucose with VILD vs PLBO, when the infusion rate of ID glucose increased from 2 to 4 kcal/min. All analyses were performed with SPSS Statistics (version 21; IBM). Data are presented as mean Ϯ SEM. P Ͻ .05 was considered statistically significant.
Results
All subjects tolerated the study well. As mentioned, 1 subject suffered an acute coronary syndrome 5 days after the second visit (on which PLBO was administered), and was subsequently excluded from the study.
Plasma glucose concentrations
Before ID glucose infusion (at t ϭ Ϫ60 and 0 min), fasting plasma glucose did not differ between the 4 study days (Table 1) . During ID glucose infusion (t ϭ 0 -120 min), plasma glucose concentrations increased promptly before declining on each study day, with both the peak and iAUC being higher during ID4 compared with ID2 (P Ͻ .001 for both) and lower after VILD vs PLBO (P Ͻ .001 for both). Moreover, there were significant interactions between the infusion rate of ID glucose and treatment with VILD on both the peak and iAUC for plasma glucose (P ϭ .003 and P ϭ .026, respectively). Although the peak and iAUC were reduced by VILD during both ID2 (P ϭ .015 and P ϭ .013) and ID4 (P Ͻ .001 and P ϭ .001), the magnitude of the reductions was approximately 3.3-fold greater during ID4 than ID2 (P ϭ .003 and P ϭ .025) ( Table 2 and Figure 2A ).
Plasma insulin and C-peptide concentrations, ISR, and the ISR to glucose ratio
Before ID glucose infusion (at t ϭ Ϫ60 and 0 min), neither fasting plasma insulin, C-peptide, ISR, nor the ISR to glucose ratio differed between the 4 study days (Table  1) . During ID glucose infusion (t ϭ 0 -120 min), plasma insulin, C-peptide, ISR, and the ISR to glucose ratio increased gradually, with the iAUC for each being higher in response to ID4 compared with ID2 (P Ͻ .001 for each). Compared with PLBO, VILD was also associated with increases in the iAUCs for plasma insulin, C-peptide, ISR, and the ISR to glucose ratio (P ϭ .001 for each), but there was no significant interaction between the infusion rate of ID glucose and treatment with VILD (Table 2 and 
Plasma glucagon concentrations
Before ID glucose infusion (at t ϭ Ϫ60 and 0 min), fasting plasma glucagon did not differ between the 4 study days. During ID glucose infusion (t ϭ 0 -120 min), plasma glucagon concentrations decreased slightly during ID2 but press.endocrine.org/journal/jcem 4771 increased gradually during ID4. There was a significant treatment effect of the glucose infusion rate (P Ͻ .001) but not treatment with VILD, on the iAUC for plasma glucagon, without any interaction between them (Table 2 and Figure 2D ).
Plasma total GIP concentrations
Before ID glucose infusion (at t ϭ Ϫ60 and 0 min), fasting plasma total GIP did not differ between the 4 study days. During ID glucose infusion (t ϭ 0 -120 min), plasma total GIP concentrations increased promptly and plateaued between t ϭ 30 and 120 minutes, with the iAUC being higher during ID4 compared with ID2 (P Ͻ .001). VILD tended to reduce the iAUC for plasma total GIP (P ϭ .062). Moreover, there was a significant interaction between the infusion rate of ID glucose and treatment with VILD on the iAUC for total GIP (P ϭ .010), such that the iAUC was less for VILD vs PLBO during ID4 (P ϭ .014) but not ID2. Accordingly, the magnitude of reduction in the iAUC after VILD compared with PLBO was greater during ID4 compared with ID2 (P ϭ .010) ( Table 2 and Figure 4A ).
Plasma total and intact GLP-1 concentrations
Before ID glucose infusion (at t ϭ Ϫ60 and 0 min), neither fasting plasma total nor intact GLP-1 differed between the 4 study days. During ID glucose infusion (t ϭ 0 -120 min), plasma total and intact GLP-1 concentrations increased minimally during ID2, but substantially during ID4, with the iAUC being higher in response to the latter (P Ͻ .001 for both). VILD increased the iAUC for intact GLP-1 (P ϭ .004) but decreased the iAUC for total GLP-1 (P ϭ .008). There were significant interactions between the infusion rate of ID glucose and treatment with VILD on the iAUC for both total and intact GLP-1 (P ϭ .013 and P ϭ .002), such that the increase in intact GLP-1 and the reduction in total GLP-1 after VILD compared with PLBO were significant during ID4 (P ϭ .006 and P ϭ .002) but not during ID2. Accordingly, the relative increase in intact GLP-1 and decrease in total GLP-1 after VILD compared with PLBO were greater during ID4 than ID2 (P ϭ .002 and P ϭ .013) ( Table 2 and Figure 4 , B and C).
Relationships between the changes in plasma glucose and incretin hormones
Compared with PLBO, the changes in the iAUC for plasma glucose with VILD (ie, the iAUC on the VILD days minus the iAUC on the PLBO days) during both ID2 and ID4 were related inversely to those for plasma intact GLP-1 (r ϭ Ϫ0.37, P Ͻ .05) and directly to those for plasma total GLP-1 and total GIP (r ϭ 0.49, P Ͻ .01 and r ϭ 0.51, P Ͻ .01, respectively) but not to those for plasma insulin or C-peptide.
Discussion
There is a substantial interindividual variation in the glycemic response to DPP-4 inhibition in type 2 diabetes, which is poorly understood. The rate of gastric emptying, which is known to be a key determinant of postprandial One-factor repeated-measures ANOVA was used to determine statistical difference. Data are mean Ϯ SEM; n ϭ 16.
incretin secretion, also exhibits a large interindividual variation (33) , and may, accordingly, influence the efficacy of DPP-4 inhibitors. In the present study, we employed ID glucose infusions at rates approximating the low-mid and upper ends of the physiological range of gastric emptying (34) and compared the acute effect of the DPP-4 inhibitor VILD on plasma glucose in a cohort of patients with type 2 diabetes, who were relatively well controlled by diet alone. The major findings were that the rate of entry of glucose into the small intestine has a major impact on the capacity of VILD to lower blood glucose, attributable to increased secretion of intact GLP-1. The implication of these observations is that DPP-4 inhibitors may be more effective in reducing postprandial glycemia in patients with type 2 diabetes, who have relatively more rapid gastric emptying. Consistent with our previous studies (3, 22) , an increase in the rate of ID glucose delivery from 2 to 4 kcal/ min was accompanied by a marked increment in plasma insulin secretion, so that the glycemic response to ID4 was proportionally less than might be expected when compared with ID2. We have recently shown in similarly wellcontrolled type 2 patients that this enhanced insulin response is primarily driven by the incretin effect, which is markedly impaired in response to ID2, but less so in response to ID4, compared with healthy subjects (3). As previously (3, 22, 24) , ID2 induced substantial GIP but minimal GLP-1 release, whereas ID4 stimulated substantial secretion of both GIP and GLP-1, although, as noted previously, the GLP-1 response occurred relatively later compared with GIP. Due to the impaired insulinotropic response to GIP in type 2 diabetes, but relatively intact response to GLP-1 (4), GLP-1 would appear to be progressively more important than GIP in driving the incretin effect and regulating blood glucose as the rate of gastric emptying of carbohydrate increases. Two-factor repeated-measures ANOVA, with ID glucose and drug as factors, was used to determine statistical difference between the 4 study days. Post hoc comparisons were adjusted by Bonferroni's correction, when ANOVA revealed a significant interaction; n ϭ 16. *, P Ͻ .05; **, P Յ .01; ***, P Յ .001, for PLBO vs VILD during ID glucose at 2 or 4 kcal/min. Paired Student's t test was used to compare the effects of VILD during ID infusion of glucose at 2 vs 4 kcal/min, with #, P Ͻ .05 and ##, P Յ .01. Data are mean Ϯ SEM.
doi: 10.1210/jc.2016-2813 press.endocrine.org/journal/jcem 4773 Interestingly, ID4 was also associated with increased plasma glucagon levels, in contrast to a modest reduction in plasma glucagon during ID2. The increase in glucagon during ID4 is unlikely to be due to cross-reactivity with other proglucagon gene products (such as oxyntomodulin or glicentin) (35) . This phenomenon was also noted in our previous work (3), and it would favor an increase in blood glucose. Although this may reflect the imbalance of the effects of GIP, which stimulates glucagon, and GLP-1, which suppresses it (36), emerging evidence suggests that glucagon itself might be secreted from the gut in response to stimulation by intraluminal nutrients (37) . In any case, the rate of carbohydrate entry into the small intestine clearly has a major impact on postabsorptive glucagon levels.
In support of our hypothesis, the glucose-lowering efficacy of VILD was substantially improved by increasing the infusion rate of ID glucose; VILD lowered both the peak and iAUC for plasma glucose substantially compared with PLBO during ID4 but only modestly during ID2, such that the magnitude of glucose lowering was over 3-fold greater during ID4 than ID2. The improvement in plasma glucose was in line with the increment in plasma intact GLP-1 as well as reductions in plasma total GLP-1 and GIP. Despite the suppression of overall GLP-1 secretion by VILD, probably due to negative feedback (1), the increase in plasma intact GLP-1 with VILD compared with PLBO was almost 4-fold greater during ID4 vs ID2. Plasma intact GIP was not assayed in the present study but would be expected to increase after VILD during ID2, as we observed after sitagliptin during ID2 (26) , and probably to an even greater degree during ID4, as the feedback suppression of plasma total GIP was evident during ID4 but not so much during ID2.
Although the current study was designed to evaluate the glucose-lowering efficacy of DPP-4 inhibition in relation to the rate of glucose entry into the small intestine, it does not allow us to determine whether the lowering of plasma glucose by VILD was mediated exclusively by GLP-1 or whether GIP made any contribution, particularly during ID4. Clarification of these issues would require concurrent administration of GLP-1 and/or GIP receptor antagonists. Unfortunately, GIP receptor antagonists suitable for human use are not currently available. Although stimulation of endogenous GLP-1 secretion has been shown to potentiate glucose lowering by DPP-4 inhibitors (18, 19) , recent studies employing the GLP-1 receptor antagonist, exendin(9 -39), suggest that GLP-1 accounts for only approximately 50% of the insulinotropic and glucose-lowering effects associated with DPP-4 inhibition in patients with type 2 diabetes (16, 17) . Several other DPP-4 substrates (eg, oxyntomodulin, pituitary adenylate cyclase activating peptide, and stromal cell-derived factor-1␣) (38) may, like the incretin hormones, contribute to the lowering of glucose by VILD. It is, therefore, not surprising that the relationship we observed between the reduction in plasma glucose and the increment in plasma intact GLP-1 was modest. Although plasma intact GIP was not measured in the present study, other studies have consistently shown that DPP-4 inhibition is associated with increased levels of intact GIP (18, 26) . Although the insulinotropic effect of GIP may be partially preserved in patients with well-controlled type 2 diabetes such as ours (6), the increment in insulin secretion (ie, ISR and ISR to glucose) with VILD in response to doubling the rate of small intestinal glucose entry was modest, even though plasma glucose exceeded the "threshold" for GLP-1-and GIPmediated insulin release. Therefore, the substantial reduction in plasma glucose with VILD during ID4 compared with ID2 was unlikely to be driven exclusively by insulin. In contrast to our recent study involving oral ingestion of a standardized semisolid meal in metformin-treated type 2 diabetic patients, in which VILD reduced plasma glucagon modestly (18), we did not observe any effect of VILD on plasma glucagon. The discrepancy is likely to be related to the differences in the experimental design. In the current study, the glucagonostatic effect of intact GLP-1 induced by VILD may have been counteracted by the profound concur- Figure 3 . Effects of VILD or PLBO (given at t ϭ Ϫ60 min) on ISR (A) and ISR to glucose ratio (B) during ID infusion of glucose at rates of 2 and 4 kcal/min (ID2 and ID4; t ϭ 0 -120 min) in patients with type 2 diabetes (n ϭ 16). Repeated-measures ANOVA was used to determine statistical difference. Results of ANOVA are reported as P values for differences by treatment (A), differences over time (B), and differences due to interaction of experiment and time (AB). Post hoc comparisons were adjusted by Bonferroni-Holm's correction; *, P Ͻ .05, for ID glucose at 2 vs 4 kcal/min in the presence of PLBO; #, P Ͻ .05, PLBO vs VILD during ID2; ␦, P Ͻ .05, PLBO vs VILD during ID4. Data are mean Ϯ SEM. Effects of VILD or PLBO (given at t ϭ Ϫ60 min) on plasma total GIP (A), plasma total GLP-1 (B), and plasma intact GLP-1 (C) during ID infusion of glucose at rates of 2 and 4 kcal/min (ID2 and ID4; t ϭ 0 -120 min) in patients with type 2 diabetes (n ϭ 16). Repeated-measures ANOVA was used to determine statistical difference. Results of ANOVA are reported as P values for differences by treatment (A), differences over time (B), and differences due to interaction of experiment and time (AB). Post hoc comparisons were adjusted by Bonferroni-Holm's correction; *, P Ͻ .05, for ID glucose at 2 vs 4 kcal/min in the presence of PLBO; #, P Ͻ .05, PLBO vs VILD during ID2; ␦, P Ͻ .05, PLBO vs VILD during ID4. Data are mean Ϯ SEM. press.endocrine.org/journal/jcem 4775 rent stimulation of intact GIP. In any case, the lowering of plasma glucose by VILD was unlikely accounted for by suppression of glucagon. Therefore, it remains likely that VILDstimulated GLP-1 lowered plasma glucose, at least partly, via pathways that are independent of both insulin and glucagon, including suppression of endogenous glucose production and enhancement of peripheral glucose uptake (12, 39) . Although VILD may be associated with a modest delay in gastric emptying (18) , this was circumvented in the current experimental model. That VILD reduced plasma glucose substantially during ID4 indicates that the ability of DPP-4 inhibitors to lower postprandial glycemia is unlikely to be driven primarily by slowing gastric emptying. Indeed, the magnitude of delay in gastric emptying induced by DPP-4 inhibitors has been reported to be either insignificant (17, 19, 25) or modest (16, 18) , probably because DPP-4 inhibition also leads to reduced formation of peptide YY(3-36) from (1-36), which favors acceleration of gastric emptying (40) , and because sustained exposure to GLP-1 during prolonged DPP-4 inhibition may lead to tachyphylaxis for its effect on gastric emptying (41) .
In interpreting the findings of this proof-of-concept study, several limitations should be noted. First, glucose entry into the small intestine was standardized by infusing through an ID catheter, which is, by definition, a nonphysiological model. In addition, we infused glucose rather than a mixed meal to control for potential confounding factors, such as meal composition and variations in digestion between individuals, and glucose does not represent a physiological meal. It would be of interest to evaluate the glucose-lowering efficacy of DPP-4 inhibitors in type 2 diabetic patients with various rates of gastric emptying or in response to pharmacological agents that affect gastric emptying, particularly the rise in blood glucose on DPP-4 inhibition is related to gastric emptying (25) . Moreover, we studied patients with type 2 diabetes who were relatively well controlled by diet alone. It would be of interest to extend our study to patients using hypoglycemic medications (eg, metformin) (42) . Although the number of subjects was relatively small, the effects observed were clear-cut, so increasing the sample size would be unlikely to lead to different conclusions. However, only acute effects were evaluated in the current study, and further long-term studies are required to clarify the clinical efficacy of DPP-4 inhibitors in relation to the rate of gastric emptying.
In conclusion, the observations made in the current study provide strong evidence that the rate of glucose entry into the small intestine (ie, the rate of gastric emptying) is a major determinant of the magnitude of lowering of plasma glucose by DPP-4 inhibition, warranting further studies with chronic exposure to a DPP-4 inhibitor to clarify whether type 2 diabetic patients with relatively more rapid gastric emptying have a greater glycemic response to treatment with DPP-4 inhibitors. Given that there is a substantial interindividual, but lesser intraindividual, variation in the rate of gastric emptying in patients with type 2 diabetes (33), these findings are of clinical relevance when taking an individualized approach to diabetes management, as advocated by the American Diabetes Association and European Association for the Study of Diabetes (43) .
